Literature DB >> 24403307

Identification of past and recent parvovirus B19 infection in immunocompetent individuals by quantitative PCR and enzyme immunoassays: a dual-laboratory study.

Peter A C Maple1, Lea Hedman, Pravesh Dhanilall, Kalle Kantola, Visa Nurmi, Maria Söderlund-Venermo, Kevin E Brown, Klaus Hedman.   

Abstract

Parvovirus B19 (B19V) is a member of the family Parvoviridae, genus Erythrovirus. B19V-specific IgG and IgM react differently against conformational and linear epitopes of VP1 and VP2 antigens, leading to the development of IgG avidity and epitope type specificity (ETS) enzyme immunoassays (EIAs) for distinguishing past from recent infection. Additionally, B19V viral load determination (by quantitative PCR [qPCR]) is increasingly used in the staging of B19V infection. In this study, the utility of these methods is compared. A panel of 78 sera was jointly tested by the Virus Reference Department (VRD), London, United Kingdom, and the Haartman Institute (HI), Helsinki, Finland, using a number of EIAs, e.g., B19V-specific IgG and IgM, IgG avidity, and ETS EIAs. At VRD, the sera were also tested by a B19V viral load PCR (qPCR). By consensus analysis, 43 (55.1%) sera represented past infection, 28 (35.9%) sera represented recent infection, and 7 (9.0%) sera were indeterminate. Both VRD B19V qPCR and HI B19V VP2 IgM EIA gave the highest agreement with consensus interpretation for past or recent infection, with an overall agreement of 99% (95% confidence interval [CI], 92 to 100) and positive predictive value (PPV) of 100% (95% CI, 87 to 100). Nine sera designated as representing past infection by consensus analysis were B19V IgM positive by a commercial VRD B19V IgM EIA and B19V IgM negative by a new HI in-house B19V VP2 IgM EIA. A new VRD B19V IgG avidity EIA showed good (>95%) agreement (excluding equivocal results) with consensus interpretations for past or recent infection. Correct discrimination of past from recent B19V infection was achieved through application of qPCR or by appropriate selection of EIAs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24403307      PMCID: PMC3957764          DOI: 10.1128/JCM.02613-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  A new method with general diagnostic utility for the calculation of immunoglobulin G avidity.

Authors:  M H Korhonen; J Brunstein; H Haario; A Katnikov; R Rescaldani; K Hedman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  The 80th year of fifth disease.

Authors:  P P Mortimer
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-11

3.  Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.

Authors:  Martin Enders; Gunnar Schalasta; Carola Baisch; Andrea Weidner; Laura Pukkila; Leena Kaikkonen; Hilkka Lankinen; Lea Hedman; Maria Söderlund-Venermo; Klaus Hedman
Journal:  J Clin Virol       Date:  2005-12-05       Impact factor: 3.168

4.  Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein.

Authors:  Jun Lu; Ning Zhi; Susan Wong; Kevin E Brown
Journal:  J Infect Dis       Date:  2006-01-19       Impact factor: 5.226

5.  Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients.

Authors:  F Watzinger; M Suda; S Preuner; R Baumgartinger; K Ebner; L Baskova; H G M Niesters; A Lawitschka; T Lion
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.

Authors:  Matthias F C Beersma; Eric C J Claas; Tamara Sopaheluakan; Aloys C M Kroes
Journal:  J Clin Virol       Date:  2005-09       Impact factor: 3.168

7.  Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity.

Authors:  M Söderlund; C S Brown; B J Cohen; K Hedman
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

8.  Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.

Authors:  M Söderlund; C S Brown; W J Spaan; L Hedman; K Hedman
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

Review 9.  Parvovirus B19 infection in pregnancy.

Authors:  Eveline P de Jong; Timo R de Haan; Aloys C M Kroes; Matthias F C Beersma; Dick Oepkes; Frans J Walther
Journal:  J Clin Virol       Date:  2006-02-20       Impact factor: 3.168

10.  Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).

Authors:  B J Cohen; P P Mortimer; M S Pereira
Journal:  J Hyg (Lond)       Date:  1983-08
View more
  11 in total

Review 1.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Use of oral fluid samples for the investigation of outbreaks of human parvovirus B19 infection.

Authors:  Daiana Lima Almada; Arthur Daniel Rocha Alves; Luciane Almeida Amado Leon; Débora Familiar Rodrigues Macedo; Solange Artimos de Oliveira; Marilda Mendonça Siqueira; David Brown; Rita de Cássia Nasser Cubel Garcia
Journal:  Braz J Microbiol       Date:  2022-09-23       Impact factor: 2.214

3.  Evaluation of Molecular Test for the Discrimination of "Naked" DNA from Infectious Parvovirus B19 Particles in Serum and Bone Marrow Samples.

Authors:  Arthur Daniel Rocha Alves; Barbara Barbosa Langella; Mariana Magaldi de Souza Lima; Wagner Luís da Costa Nunes Pimentel Coelho; Rita de Cássia Nasser Cubel Garcia; Claudete Aparecida Araújo Cardoso; Renato Sergio Marchevsky; Marcelo Alves Pinto; Luciane Almeida Amado
Journal:  Viruses       Date:  2022-04-18       Impact factor: 5.818

Review 4.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

5.  A protein L-based immunodiagnostic approach utilizing time-resolved Förster resonance energy transfer.

Authors:  Satu Hepojoki; Visa Nurmi; Antti Vaheri; Klaus Hedman; Olli Vapalahti; Jussi Hepojoki
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

6.  Extinct type of human parvovirus B19 persists in tonsillar B cells.

Authors:  Lari Pyöriä; Mari Toppinen; Elina Mäntylä; Lea Hedman; Leena-Maija Aaltonen; Maija Vihinen-Ranta; Taru Ilmarinen; Maria Söderlund-Venermo; Klaus Hedman; Maria F Perdomo
Journal:  Nat Commun       Date:  2017-04-04       Impact factor: 14.919

7.  Transient aplastic crisis triggered by parvovirus B19 in a family with hereditary spherocytosis.

Authors:  Nicolas Cilla; Léa Domitien; Neila Arrada; Delphine Chiffre; Perrine Mahe; Laure Vincent; Patricia Aguilar-Martinez; Vincent Foulongne
Journal:  IDCases       Date:  2020-05-11

8.  Microsphere-Based IgM and IgG Avidity Assays for Human Parvovirus B19, Human Cytomegalovirus, and Toxoplasma gondii.

Authors:  Yilin Wang; Lea Hedman; Visa Nurmi; Inga Ziemele; Maria F Perdomo; Maria Söderlund-Venermo; Klaus Hedman
Journal:  mSphere       Date:  2020-03-18       Impact factor: 4.389

9.  A cross-sectional study on risk factors for infection with Parvovirus B19 and the association with anaemia in a febrile paediatric population in Ghana.

Authors:  Wiebke Herr; Ralf Krumkamp; Benedikt Hogan; Denise Dekker; Kennedy Gyau; Ellis Owusu-Dabo; Nimako Sarpong; Anna Jaeger; Wibke Loag; Doris Winter; Charity Wiafe Akenten; Daniel Eibach; Helmut Fickenscher; Anna Eis-Hübinger; Jürgen May; Benno Kreuels
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

10.  Prevalence and Phylogenetic Analysis of Parvovirus (B19V) among Blood Donors with Different Nationalities Residing in Qatar.

Authors:  Doua Abdelrahman; Duaa W Al-Sadeq; Maria K Smatti; Sara A Taleb; Raed O AbuOdeh; Enas S Al-Absi; Asmaa A Al-Thani; Peter V Coyle; Nader Al-Dewik; Ahmed A Al Qahtani; Hadi M Yassine; Gheyath K Nasrallah
Journal:  Viruses       Date:  2021-03-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.